Cell Therapy Facility

science, Singapore

Cell Therapy Facility

science, Singapore
SEARCH FILTERS
Time filter
Source Type

VANCOUVER, BC--(Marketwired - May 19, 2017) - Mining for Miracles, the BC mining community's longstanding fundraising campaign for BC Children's Hospital, raised $1,156,730 on May 18 at its signature event -- the Teck Celebrity Pie Throw. Participants raised funds by volunteering to take a pie in the face while asking friends, family and colleagues to pledge their support. This year, representatives from Teck, Goldcorp, Eldorado Gold, Atlantic Gold, Capstone, Fednav, Hatch, Golder, Fluor, Tetra Tech, CWA Engineers, Finning, Ausenco, Amec Foster Wheeler, Cassels Brock, Blakes, and the Mining Suppliers Association of BC participated in the Pie Throw. "The Teck Celebrity Pie Throw is such a fun, high spirited, community event that unites the mining industry for a great cause -- the health and well-being of BC's children," said Teri Nicholas, President and CEO of BC Children's Hospital Foundation. "We can always rely on them to draw a crowd, and inspire the philanthropy that transforms the lives of children and families who rely on BC Children's Hospital." "The success of Pie Throw is truly a testament to the generosity of the mining industry," said Joanne Klein, co-chair, Mining for Miracles and Vice President, People at Goldcorp. "As a former Pie Throw participant, I can tell you that friends, family and supporters of the industry make it possible, and they have done it again this year." "For the past fifteen years, Pie Throw has brought together representatives from across the mining industry in support of BC's sick and injured children," said Jeff Hanman, co-chair, Mining for Miracles and Vice President, Corporate Affairs at Teck. "We were proud to exceed our fundraising goal of $800,000, which will go to creating the new TRACE program at BC Children's Hospital." In 2017 and 2018, Mining for Miracles will raise approximately $2.9 million to support the development of TRACE. TRACE will work towards providing children across British Columbia with personalized medicine using the patient's own cells to prevent rejection of organ transplants, kill cancer cells and fight infection. Mining for Miracles funding will establish two state of the art facilities for the TRACE program, giving children in British Columbia access to the best and most current cell therapies and enabling BC Children's Hospital and its Research Institute to develop new and better cell therapy and transplantation technologies. 100% of funds raised at Pie Throw will go to developing TRACE. The partnership of BC Children's Hospital Foundation and Mining for Miracles is a leading example of how industry, institutions and social-profit organizations can work together to provide world-class health care to children and families across BC. Every year volunteers from the mining community work together through Mining for Miracles to help improve the quality of health care for children in our province. Through its support of the construction of facilities and acquisition of specialized medical equipment at the hospital, Mining for Miracles is helping to keep BC Children's Hospital at the forefront of pediatric care excellence. Visit www.miningformiracles.ca for more information and to donate. BC Children's Hospital is the province's only full-service acute-care pediatric hospital. Last year, BC Children's Hospital treated more than 84,000 children. The money raised by the foundation supports BC Children's Hospital, its research institute, and Sunny Hill Health Centre for Children. For more information, visit www.bcchf.ca. Through Mining for Miracles support, TRACE will establish two state of the art facilities, a Translational Biomarker Facility and a Clinical Cell Therapy Facility. As an example, a child who has received a kidney transplant currently needs multiple biopsies to screen for early signs of rejection. This is an invasive process that requires deep sedation and a hospital stay. With the establishment of the Translational Biomarker Facility, it is anticipated that in the near future, a simple urine test will become a first line of surveillance to understand if the transplanted organ is at risk of being rejected. The infrastructure enabled by the TRACE Program, will give children and families access to the best and most current therapies available. It will also enable BC Children's Hospital Research Institute to become a leader in cell therapies and transplantation for children in BC. Image Available: http://www.marketwire.com/library/MwGo/2017/5/18/11G139290/Images/BD-TECK-5424-6270e6fbf2cb85778fcc7249ce5a0cb6.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/5/18/11G139290/Images/BD-TECK-5306-0bbee829b4c982f18bdb2c8cbed9f7d1.jpg Image Available: http://www.marketwire.com/library/MwGo/2017/5/18/11G139290/Images/BD-TECK-5236-167f8f405b00a1afa1f3ff228e6447e2.jpg


Kolle S.-F.T.,Copenhagen University | Fischer-Nielsen A.,Cell Therapy Facility | Mathiasen A.B.,Heart Center | Elberg J.J.,Copenhagen University | And 7 more authors.
The Lancet | Year: 2013

Background Autologous fat grafting is increasingly used in reconstructive surgery. However, resorption rates ranging from 25% to 80% have been reported. Therefore, methods to increase graft viability are needed. Here, we report the results of a triple-blind, placebo-controlled trial to compare the survival of fat grafts enriched with autologous adiposederived stem cells (ASCs) versus non-enriched fat grafts. Methods Healthy participants underwent two liposuctions taken 14 days apart: one for ASC isolation and ex-vivo expansion, and another for the preparation of fat grafts. Two purified fat grafts (30 mL each) taken from the second liposuction were prepared for each participant. One graft was enriched with ASCs (20 ×106 cells per mL fat), and another graft without ASC enrichment served as a control. The fat grafts were injected subcutaneously as a bolus to the posterior part of the right and left upper arm according to the randomisation sequence. The volumes of injected fat grafts were measured by MRI immediately after injection and after 121 days before surgical removal. The primary goal was to compare the residual graft volumes of ASC-enriched grafts with those of control grafts. This study is registered at www.clinicaltrialsregister.eu, number 2010-023006-12. Findings 13 participants were enrolled, three of whom were excluded. Compared with the control grafts, the ASCenriched fat grafts had significantly higher residual volumes: 23·00 (95% CI 20· 57-25· 43) cm3 versus 4· 66 (3· 16-6· 16) cm3 for the controls, corresponding to 80· 9% (76· 6-85· 2) versus 16· 3% (11· 1-21· 4) of the initial volumes, respectively (p<0· 0001). The difference between the groups was 18· 34 (95% CI 15· 70-20· 98) cm3, equivalent to 64· 6% (57· 1-72· 1; p<0· 0001). No serious adverse events were noted. Interpretation The procedure of ASC-enriched fat grafting had excellent feasibility and safety. These promising results add significantly to the prospect of stem cell use in clinical settings, and indicate that ASC graft enrichment could render lipofilling a reliable alternative to major tissue augmentation, such as breast surgery, with allogeneic material or major fl ap surgery.


Linn Y.-C.,Singapore General Hospital | Yong H.-X.,Singapore General Hospital | Niam M.,Cell Therapy Facility | Lim T.-J.,Cell Therapy Facility | And 11 more authors.
Cytotherapy | Year: 2012

Background aims. Cytokine-induced killer (CIK) cells have shown remarkable cytotoxicity against various tumors in vitro and in animal studies. We report on the clinical outcome of autologous CIK cells for patients with acute (AML) and chronic (CML) myeloid leukemia in remission. Methods. Eleven of the 13 recruited AML patients undergoing autologous peripheral blood stem cell transplant (autoPBSCT) were given autologous CIK cell infusion upon engraftment post-transplant and followed-up for disease relapse. Eleven CML patients on Imatinib with residual disease detectable by polymerase chain reaction (PCR) were given infusion and monitored by quantitation of the bcr-abl transcript. Results. Despite the presence of interferon (IFN)-γ-secreting T cells against various AML- and CML-associated peptides at sporadic time-points and demonstration of in vitro cytotoxicity of CIK cells against autologous and allogeneic AML targets, there was no survival benefit in AML patients post-autoPBSCT given CIK cells compared with historical controls. For CML patients, all continued to have a detectable bcr-abl transcript fluctuating within a range comparable to their pre-treatment baseline, although two had a transient but non-sustainable disappearance of bcr-abl transcript. There were no adverse reactions except for fever within the first day of infusion. Conclusions. Our small series, while confirming safety, failed to demonstrate a clinical benefit of autologous CIK cells given in its current form for AML and CML. Further manipulation of CIK cells to improve anti-leukemic potency and specificity, together with the preparation of patients to create a more conducive milieu for in vivo expansion and persistence of infused CIK cells, should be explored. © 2012 Informa Healthcare.


Niam M.,Cell Therapy Facility | Linn Y.-C.,Singapore General Hospital | Fook Chong S.,Singapore General Hospital | Lim T.-J.,Cell Therapy Facility | And 6 more authors.
Experimental Hematology | Year: 2011

Objective: In our clinical studies involving cytokine-induced killer (CIK) cells for patients with hematological malignancies, starting cells came from a heterogeneous group of patients and donors. Here we study the feasibility of expansion and analyzed the characteristics of the end product from starting cells derived from different sources and at different disease states. Materials and Methods: Seventy-five clinical scale cultures were grown from 28 patients and 20 donors in Good Manufacturing Practices facilities under CIK condition. Results: CIK cells could be successfully expanded from healthy donors, patients with acute myeloid leukemia recovering from chemotherapy, untreated patients with acute myeloid leukemia or myelodysplastic syndrome with circulating leukemic blasts, and patients with chronic myeloid leukemia on imatinib. Furthermore, CIK cells of donor origin could be expanded from leukapheresis product collected from patients who relapsed post-allogeneic transplantation, thereby offering a useful method of obtaining activated donor cells in patients for whom further donor cells were unavailable. Interestingly, CIK cells cultured from patients with untreated acute myeloid leukemia and myelodysplastic syndrome had a significantly higher proportion of CD3 +CD56 + subset and higher fold expansion of CD3 + cells as compared to other groups of patients or healthy donors. Multivariate analysis showed that fresh starting cells expanded better than frozen-thawed cells, while prior exposure to granulocyte colony-stimulating factor or imatinib before harvesting did not adversely affect CIK cell expansion. Conclusions: Clinical scale expansion of CIK cells is feasible from both healthy donors and leukemia patients at various stages of treatment. This robust system allows clinical translation using CIK cells as immunotherapy in various clinical settings. © 2011 ISEH - Society for Hematology and Stem Cells.


In our clinical studies involving cytokine-induced killer (CIK) cells for patients with hematological malignancies, starting cells came from a heterogeneous group of patients and donors. Here we study the feasibility of expansion and analyzed the characteristics of the end product from starting cells derived from different sources and at different disease states.Seventy-five clinical scale cultures were grown from 28 patients and 20 donors in Good Manufacturing Practices facilities under CIK condition.CIK cells could be successfully expanded from healthy donors, patients with acute myeloid leukemia recovering from chemotherapy, untreated patients with acute myeloid leukemia or myelodysplastic syndrome with circulating leukemic blasts, and patients with chronic myeloid leukemia on imatinib. Furthermore, CIK cells of donor origin could be expanded from leukapheresis product collected from patients who relapsed post-allogeneic transplantation, thereby offering a useful method of obtaining activated donor cells in patients for whom further donor cells were unavailable. Interestingly, CIK cells cultured from patients with untreated acute myeloid leukemia and myelodysplastic syndrome had a significantly higher proportion of CD3(+)CD56(+) subset and higher fold expansion of CD3(+) cells as compared to other groups of patients or healthy donors. Multivariate analysis showed that fresh starting cells expanded better than frozen-thawed cells, while prior exposure to granulocyte colony-stimulating factor or imatinib before harvesting did not adversely affect CIK cell expansion.Clinical scale expansion of CIK cells is feasible from both healthy donors and leukemia patients at various stages of treatment. This robust system allows clinical translation using CIK cells as immunotherapy in various clinical settings.

Loading Cell Therapy Facility collaborators
Loading Cell Therapy Facility collaborators